Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen Inc.
In the first part of this study, patients in the 2 groups were tested to see if there was a difference in the response to treatment and whether there were differences in the side effects (unwanted effects).
The second and third parts of the study are being done to see if there are any side effects (unwanted effects) of the higher dose of brentuximab vedotin when combined with a modified version of RCHOP that omits vincristine. The third part of the study is being done to see if there is a difference between BV+RCHP and RCHOP in the response to treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treatment-naive patients with systemic de novo or transformed diffuse large B cell lymphoma (DLBCL) or follicular non-Hodgkin lymphoma (NHL) grade 3b
International Prognostic Index (IPI) score greater than or equal to 3 for patients greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients less than or equal to 60 years of age
Stage IAX (bulk defined as single lymph node mass \>10 cm in diameter), IB-IV disease
Measurable disease of at least 1.5 cm
Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Patients in Parts 2 and 3 must have histologically confirmed diagnosis of CD30-positive DLBCL
You may not be if
Previous history of treated indolent lymphoma
History of another primary malignancy that has not been in remission for 3 years
Clareo Health | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
